FGFR inhibitors for advanced cholangiocarcinoma

• Published in: The lancet oncology Vol. 21; no. 5; pp. 610 - 612
• Main Authors: Yang, Tian, Liang, Lei, Wang, Ming-Da, Shen, Feng
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2020; Elsevier Limited
• Subjects: Chemotherapy; Cholangiocarcinoma; Clinical trials; Disease control; Drug resistance; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Fibroblast growth factor receptors; Growth factor receptors; Growth factors; Hematology, Oncology, and Palliative Medicine; Kinases; Medical prognosis; Metastases; Metastasis; Molecular modelling; Mutation; Next-generation sequencing; Oncology; Platelet-derived growth factor; Platelet-derived growth factor receptors; Signal transduction; Survival; Translocation; Tyrosine; Vascular endothelial growth factor; Vascular endothelial growth factor receptors

The prognosis of advanced or metastatic cholangiocarcinoma is extremely unsatisfactory, mainly owing to few treatment options and poor responses to conventional chemotherapy regimens.1 Since 2007, advances in next-generation sequencing have substantially improved the ability to understand the comple...